A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability progression.

Abstract: Spiking neural P systems (SN P systems) abstract the structure and function of neurons and nervous systems. By adopting some biological observations or mathematical considerations in SN P ...

Alterity Therapeutics has appointed internationally recognised expert in neurodegenerative diseases Daniel O Claassen as chief medical advisor. ... Read More The post Alterity bolsters clinical ...

Another phase III failure of Theravance Biopharma Inc.’s norepinephrine reuptake inhibitor ampreloxetine to treat symptomatic neurogenic orthostatic hypotension, this time in patients with the rare ...

Theravance Biopharma shares tumble after Phase 3 trial fails, company halts drug program and explores sale options ahead of earnings.

Theravance Biopharma said on Tuesday its board is reviewing strategic alternatives, including a ​possible sale, after scrapping development of an experimental drug for ‌a rare disorder, sending its ...

In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its ...

Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease ...

Abstract: This article is concerned with the problem of safety control for switched systems, where different safe sets are allowed for different subsystems and safety is not necessarily possessed for ...

Add Yahoo as a preferred source to see more of our stories on Google. Multiple systems will bring the West beneficial rain and mountain snow. The first round moves in Wednesday into Thursday, but that ...